Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evorpacept - ALX Oncology

Next Previous
Drug Profile

Evorpacept - ALX Oncology

Alternative Names: ALX-148; CD47/SIRPa-blocking Agent ALX 148; SIRPa Variant ALX 148

Latest Information Update: 28 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alexo Therapeutics
  • Developer ALX Oncology; Eli Lilly and Company; Merck & Co; Merck Sharp & Dohme; Quantum Leap Healthcare Collaborative; University of California; Zymeworks
  • Class Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Proteins; Recombinant fusion proteins
  • Mechanism of Action CD47 antigen inhibitors; Cytotoxic T lymphocyte stimulants; Dendritic cell stimulants; Phagocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Adenocarcinoma
  • Phase II Colorectal cancer; Oropharyngeal cancer; Squamous cell cancer
  • Phase I/II Acute myeloid leukaemia; HER2 positive breast cancer; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Solid tumours
  • Phase I Breast cancer
  • No development reported Urogenital cancer

Most Recent Events

  • 28 Dec 2025 No recent reports of development identified for phase-I development in Urogenital-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
  • 07 Dec 2025 Updated efficacy data from a phase I/II trial in Non-Hodgkin's lymphoma released by ALX Oncology
  • 07 Nov 2025 Updated efficacy data from the phase II/III ASPEN-06 trial in Adenocarcinoma released by ALX Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top